相关临床试验
106
11 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2006
进行中（未招募）
6
5.7%
已完成
55
51.9%
尚未招募
5
4.7%
招募中
17
16.0%
终止
5
4.7%
Unknown
17
16.0%
撤回
1
0.9%
暂无批准数据
- A large cohort study of 109,504 gout patients found that achieving serum urate levels below 6 mg/dL within 12 months of starting urate-lowering therapy reduced major adverse cardiovascular events by 9%. - Patients who reached the target urate level demonstrated higher 5-year event-free survival rates (89.4% vs 88.3%) compared to those who did not achieve the target. - The cardiovascular benefit was most pronounced in high-risk patients and those achieving even lower urate levels below 5 mg/dL, who showed a 23% relative risk reduction. - The findings provide additional evidence supporting treat-to-target urate-lowering strategies in gout management, particularly for patients with elevated cardiovascular risk profiles.
- The ImmunoTACE phase II trial demonstrated that patients with intermediate-stage hepatocellular carcinoma who received dendritic cell vaccination alongside standard treatment experienced significantly longer progression-free survival at 18.6 months versus 10.4 months with standard care alone. - This represents the first controlled clinical trial to show that a cell-based vaccine using lab-grown dendritic cells can improve patient outcomes in liver cancer, offering a potential new treatment approach for one of the world's leading causes of cancer-related death. - The vaccine is created from patients' own white blood cells, expanded in laboratory conditions with cancer proteins to stimulate immune responses, and represents a potentially affordable and effective therapy that could complement existing checkpoint inhibitor treatments.
